Ecor1 Capital, Llc Acquires 196,438 Shares of Zymeworks Inc. (NYSE:ZYME) Stock

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc purchased 196,438 shares of the company’s stock in a transaction dated Friday, April 4th. The shares were acquired at an average price of $11.17 per share, with a total value of $2,194,212.46. Following the transaction, the director now owns 17,699,774 shares in the company, valued at approximately $197,706,475.58. The trade was a 1.12 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Wednesday, April 2nd, Ecor1 Capital, Llc bought 74,360 shares of Zymeworks stock. The stock was bought at an average cost of $11.85 per share, for a total transaction of $881,166.00.
• On Monday, March 31st, Ecor1 Capital, Llc purchased 4,397 shares of Zymeworks stock. The stock was bought at an average cost of $11.75 per share, with a total value of $51,664.75.
• On Wednesday, March 26th, Ecor1 Capital, Llc acquired 43,848 shares of Zymeworks stock. The shares were bought at an average cost of $12.24 per share, with a total value of $536,699.52.
• On Monday, March 24th, Ecor1 Capital, Llc bought 22,689 shares of Zymeworks stock. The stock was purchased at an average cost of $13.08 per share, for a total transaction of $296,772.12.
• On Friday, March 21st, Ecor1 Capital, Llc purchased 31,033 shares of Zymeworks stock. The shares were purchased at an average cost of $12.78 per share, with a total value of $396,601.74.
• On Wednesday, March 19th, Ecor1 Capital, Llc acquired 58,306 shares of Zymeworks stock. The shares were purchased at an average price of $12.64 per share, for a total transaction of $736,987.84.
• On Monday, March 17th, Ecor1 Capital, Llc bought 56,277 shares of Zymeworks stock. The stock was purchased at an average price of $12.23 per share, with a total value of $688,267.71.
• On Thursday, March 13th, Ecor1 Capital, Llc purchased 468,356 shares of Zymeworks stock. The shares were acquired at an average price of $12.48 per share, for a total transaction of $5,845,082.88.
• On Tuesday, March 11th, Ecor1 Capital, Llc acquired 320,690 shares of Zymeworks stock. The stock was acquired at an average price of $11.49 per share, with a total value of $3,684,728.10.
• On Friday, January 17th, Ecor1 Capital, Llc bought 19,748 shares of Zymeworks stock. The shares were acquired at an average cost of $13.87 per share, for a total transaction of $273,904.76.

Zymeworks Stock Performance

Shares of ZYME stock opened at $9.91 on Wednesday. Zymeworks Inc. has a fifty-two week low of $7.97 and a fifty-two week high of $17.70. The firm has a market cap of $689.51 million, a P/E ratio of -6.61 and a beta of 1.18. The business’s 50 day moving average price is $13.05 and its 200-day moving average price is $13.64.

Institutional Trading of Zymeworks

Several large investors have recently added to or reduced their stakes in ZYME. GAMMA Investing LLC lifted its position in shares of Zymeworks by 1,113.3% in the 1st quarter. GAMMA Investing LLC now owns 6,467 shares of the company’s stock worth $77,000 after purchasing an additional 5,934 shares during the period. Polar Asset Management Partners Inc. purchased a new stake in Zymeworks in the fourth quarter worth about $527,000. Voloridge Investment Management LLC purchased a new stake in Zymeworks in the fourth quarter worth about $640,000. Point72 Asset Management L.P. boosted its position in Zymeworks by 565.8% during the 4th quarter. Point72 Asset Management L.P. now owns 330,127 shares of the company’s stock valued at $4,833,000 after acquiring an additional 280,544 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its holdings in shares of Zymeworks by 0.4% during the 4th quarter. Nuveen Asset Management LLC now owns 207,023 shares of the company’s stock worth $3,031,000 after acquiring an additional 886 shares during the period. Institutional investors own 92.89% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Wells Fargo & Company upped their price target on shares of Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a research report on Thursday, December 19th. HC Wainwright increased their target price on Zymeworks from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Monday, March 10th. Lifesci Capital initiated coverage on Zymeworks in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $30.00 price target on the stock. Citigroup increased their price objective on Zymeworks from $18.00 to $19.00 and gave the company a “buy” rating in a research note on Friday, March 7th. Finally, JPMorgan Chase & Co. raised shares of Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 target price on the stock in a research note on Monday, December 16th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Zymeworks presently has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.